{"success":true,"data":{"pressRelease":{"id":"4737","rtpr_id":"nBw7L9Gf7a","ticker":"NAGE","exchange":"NASDAQ","all_tickers":["NAGE"],"title":"Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026","author":"Business Wire","published_at":"2026-04-22T12:32:00.128Z","article_body":"Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday,\nMay 6, 2026\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=1&md5=3e0435514646df32ef3da4b017ff1c86)\n(NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine\ndinucleotide) with a focus on the science of healthy aging, today announces\nthat it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET\nto discuss its financial results for the first quarter, which ended March 31,\n2026. The financial results will be reported in a press release after the\nclose of regular stock market trading hours on Wednesday, May 6, 2026.\n\nInvestor Conference Call:\n\nA live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern\nDaylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen\nBioscience’s first quarter financial results and provide a general business\nupdate.\n\nTo listen to the webcast, or to view the earnings press release and its\naccompanying financial exhibits, please visit the Investor Relations section\nof Niagen Bioscience’s website at www.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.niagenbioscience.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenbioscience.com&index=2&md5=4c90d2185acaf310773c16f86d68d827)\n. The toll-free dial-in information for this call is 1 (833) 461-5787 with\nConference ID: 828848803.\n\nThe webcast will be recorded and will be available for replay via the website\nfrom 7:30 p.m. Eastern Daylight Time on May 6, 2026, to 11:59 p.m. Eastern\nDaylight Time on May 6, 2027.\n\nDate: Wednesday, May 6\n\nTime: 4:30 p.m. ET (1:30 p.m. PT)\n\nToll-free dial-in number: +1 (833) 461-5787\n\nConference ID: 828848803\n\nWebcast link: Niagen Bioscience First Quarter Earnings Conference Call\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F828848803&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=Niagen+Bioscience+First+Quarter+Earnings+Conference+Call&index=3&md5=9488c0c524d238cc292be2d39c1d71ed)\n\nFor additional information on Niagen Bioscience, visit\nwww.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenbioscience.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenbioscience.com&index=4&md5=6144457a91959e4b4430d13dc27c64c2)\n.\n\nAbout Niagen Bioscience:\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=5&md5=48f4b9ac2fe8b920406fd299d0e96cb4)\n(NASDAQ: NAGE) is the global leader in NAD+ (nicotinamide adenine\ndinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+\ndiscoveries, Niagen Bioscience(™) is dedicated to advancing healthspan\nthrough precision science and innovative NAD+-boosting solutions.\n\nThe Niagen Bioscience team, composed of world-renowned scientists, works with\nindependent investigators from esteemed universities and research institutions\naround the globe to uncover the full potential of NAD+. A vital coenzyme found\nin every cell of the human body, NAD+ declines with age and exposure to\neveryday lifestyle stressors. NAD+ depletion is a key contributor to\nage-related changes in health and vitality.\n\nDistinguished by state-of-the-art laboratories, rigorous scientific and\nquality protocols, and collaborations with leading research institutions\nworldwide, Niagen Bioscience sets the gold standard for research, quality, and\ninnovation. There’s a better way to age.\n\nAt the heart of its clinically proven product portfolio is Niagen® (patented\nnicotinamide riboside, or NR), the most efficient, well-researched, and\nhigh-quality NAD+ booster available. Niagen powers the Company’s consumer\nsupplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the\nUnited States† (available at www.truniagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.truniagen.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.truniagen.com&index=6&md5=dcf4949abe6203f57132538654911b0b)\n), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and\ninjectable Niagen products (www.niagenplus.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenplus.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenplus.com&index=7&md5=f506c39347c0e0ed4a893c3c7b9c95cb)\n). Pharmaceutical-grade Niagen IV and injections are compounded and\ndistributed by U.S. FDA-registered 503B outsourcing facilities and are\navailable exclusively at clinics with a prescription.\n\nNiagen Bioscience’s robust patent portfolio protects NR and other NAD+\nprecursors. Niagen Bioscience maintains a website at www.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenbioscience.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenbioscience.com&index=8&md5=9d99e136eadb9b14f0e9bf4ae229a3bc)\n, where copies of press releases, news, and financial information are\nregularly published.\n\n(†)Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 –\nDec. 2025)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260422670415/en/\n(https://www.businesswire.com/news/home/20260422670415/en/)\n\nNiagen Bioscience Media Contact: \n\nKendall Knysch, Senior Director of Media Relations & Partnerships\n\n310.405.5227\n\nkendall.knysch@niagenbio.com (mailto:kendall.knysch@niagenbio.com)\n\nNiagen Bioscience Investor Relations Contact: \n\nValter Pinto, Managing Director\n\nKCSA Strategic Communications\n\n212.896.1254\n\nNiagen@kcsa.com (mailto:Niagen@kcsa.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7L9Gf7a","title":"Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026","author":"Business Wire","ticker":"NAGE","created":"2026-04-22T12:32:00.128Z","tickers":["NAGE"],"exchange":"NASDAQ","article_body":"Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday,\nMay 6, 2026\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=1&md5=3e0435514646df32ef3da4b017ff1c86)\n(NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine\ndinucleotide) with a focus on the science of healthy aging, today announces\nthat it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET\nto discuss its financial results for the first quarter, which ended March 31,\n2026. The financial results will be reported in a press release after the\nclose of regular stock market trading hours on Wednesday, May 6, 2026.\n\nInvestor Conference Call:\n\nA live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern\nDaylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen\nBioscience’s first quarter financial results and provide a general business\nupdate.\n\nTo listen to the webcast, or to view the earnings press release and its\naccompanying financial exhibits, please visit the Investor Relations section\nof Niagen Bioscience’s website at www.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.niagenbioscience.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenbioscience.com&index=2&md5=4c90d2185acaf310773c16f86d68d827)\n. The toll-free dial-in information for this call is 1 (833) 461-5787 with\nConference ID: 828848803.\n\nThe webcast will be recorded and will be available for replay via the website\nfrom 7:30 p.m. Eastern Daylight Time on May 6, 2026, to 11:59 p.m. Eastern\nDaylight Time on May 6, 2027.\n\nDate: Wednesday, May 6\n\nTime: 4:30 p.m. ET (1:30 p.m. PT)\n\nToll-free dial-in number: +1 (833) 461-5787\n\nConference ID: 828848803\n\nWebcast link: Niagen Bioscience First Quarter Earnings Conference Call\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F828848803&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=Niagen+Bioscience+First+Quarter+Earnings+Conference+Call&index=3&md5=9488c0c524d238cc292be2d39c1d71ed)\n\nFor additional information on Niagen Bioscience, visit\nwww.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenbioscience.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenbioscience.com&index=4&md5=6144457a91959e4b4430d13dc27c64c2)\n.\n\nAbout Niagen Bioscience:\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=5&md5=48f4b9ac2fe8b920406fd299d0e96cb4)\n(NASDAQ: NAGE) is the global leader in NAD+ (nicotinamide adenine\ndinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+\ndiscoveries, Niagen Bioscience(™) is dedicated to advancing healthspan\nthrough precision science and innovative NAD+-boosting solutions.\n\nThe Niagen Bioscience team, composed of world-renowned scientists, works with\nindependent investigators from esteemed universities and research institutions\naround the globe to uncover the full potential of NAD+. A vital coenzyme found\nin every cell of the human body, NAD+ declines with age and exposure to\neveryday lifestyle stressors. NAD+ depletion is a key contributor to\nage-related changes in health and vitality.\n\nDistinguished by state-of-the-art laboratories, rigorous scientific and\nquality protocols, and collaborations with leading research institutions\nworldwide, Niagen Bioscience sets the gold standard for research, quality, and\ninnovation. There’s a better way to age.\n\nAt the heart of its clinically proven product portfolio is Niagen® (patented\nnicotinamide riboside, or NR), the most efficient, well-researched, and\nhigh-quality NAD+ booster available. Niagen powers the Company’s consumer\nsupplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the\nUnited States† (available at www.truniagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.truniagen.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.truniagen.com&index=6&md5=dcf4949abe6203f57132538654911b0b)\n), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and\ninjectable Niagen products (www.niagenplus.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenplus.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenplus.com&index=7&md5=f506c39347c0e0ed4a893c3c7b9c95cb)\n). Pharmaceutical-grade Niagen IV and injections are compounded and\ndistributed by U.S. FDA-registered 503B outsourcing facilities and are\navailable exclusively at clinics with a prescription.\n\nNiagen Bioscience’s robust patent portfolio protects NR and other NAD+\nprecursors. Niagen Bioscience maintains a website at www.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenbioscience.com&esheet=54520181&newsitemid=20260422670415&lan=en-US&anchor=www.niagenbioscience.com&index=8&md5=9d99e136eadb9b14f0e9bf4ae229a3bc)\n, where copies of press releases, news, and financial information are\nregularly published.\n\n(†)Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 –\nDec. 2025)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260422670415/en/\n(https://www.businesswire.com/news/home/20260422670415/en/)\n\nNiagen Bioscience Media Contact: \n\nKendall Knysch, Senior Director of Media Relations & Partnerships\n\n310.405.5227\n\nkendall.knysch@niagenbio.com (mailto:kendall.knysch@niagenbio.com)\n\nNiagen Bioscience Investor Relations Contact: \n\nValter Pinto, Managing Director\n\nKCSA Strategic Communications\n\n212.896.1254\n\nNiagen@kcsa.com (mailto:Niagen@kcsa.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-04-22T12:32:00.204347782Z","server_sent_at_ms":1776861120204},"received_at":"2026-04-22T12:32:00.328Z","source_url":"https://www.businesswire.com/news/home/20260422670415/en/"},"analysis":{"id":"3357","press_release_id":"4737","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Niagen Bioscience announced it will release its first quarter 2026 financial results after the market closes on Wednesday, May 6, 2026.\n\nThe company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide a business update.\n\nInvestors can access the live webcast via the company's website or by dialing in using the provided conference ID.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Standard earnings date announcement for Q1 2026; no material data released."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Kendall Knysch","role":"Senior Director of Media Relations & Partnerships"},{"name":"Valter Pinto","role":"Managing Director, Investor Relations"}],"products":["Niagen","Tru Niagen","Niagen Plus"],"companies":[{"name":"Niagen Bioscience, Inc.","ticker":"NAGE"},{"name":"KCSA Strategic Communications","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of an upcoming earnings release date and conference call logistics; no financial results or material business updates provided."},"tickerRelevance":{"others":[],"primary":"NAGE"},"eventTypeSecondary":[]},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Niagen Bioscience announced it will release its first quarter 2026 financial results after the market closes on Wednesday, May 6, 2026.\n\nThe company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide a business update.\n\nInvestors can access the live webcast via the company's website or by dialing in using the provided conference ID.","key_figures":{},"named_entities":{"people":[{"name":"Kendall Knysch","role":"Senior Director of Media Relations & Partnerships"},{"name":"Valter Pinto","role":"Managing Director, Investor Relations"}],"products":["Niagen","Tru Niagen","Niagen Plus"],"companies":[{"name":"Niagen Bioscience, Inc.","ticker":"NAGE"},{"name":"KCSA Strategic Communications","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T16:17:46.953Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.173Z"}},"durationMs":58993,"modelName":"glm-4.7"}}